Table 4. Cox regression models for renal outcome of the doubling of the baseline serum creatinine.
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| Model 1 | ||||||
| eGFR (per 1 ml/min/1.73 m2 increase) | 0.96 | 0.93–0.98 | <0.001 | 0.95 | 0.93–0.98 | <0.001 |
| Urinary PCR (per 1 mg/mg increase) | 1.70 | 1.36–2.12 | <0.001 | 1.52 | 1.26–1.82 | <0.001 |
| Serum C3 (per 1 mg/dl increase) | 0.96 | 0.93–0.98 | 0.002 | - | - | - |
| Patients with hypoC3 (vs. no) | - | - | - | 3.59 | 1.56–8.28 | 0.003 |
| Model 2 | ||||||
| eGFR (per 1 ml/min/1.73 m2 increase) | 0.97 | 0.95–0.99 | 0.037 | - | - | - |
| Urinary PCR (per 1 mg/mg increase) | 1.63 | 1.27–2.08. | <0.001 | - | - | - |
| Tubular atrophy/interstitial fibrosis | - | - | - | |||
| 0–25% of cortical area (T0) | Reference | |||||
| 25–50% of cortical area (T1) | 7.632 | 0.91–63.6 | 0.061 | - | - | - |
| >50% of cortical area (T2) | 35.81 | 4.03–217.9 | 0.001 | - | - | - |
| Mesangial C3 deposition | ||||||
| 0 | Reference | |||||
| 1+ | 6.03 | 0.93–39.00 | 0.059 | - | - | - |
| 2+∼3+ | 14.24 | 2.03–99.87 | 0.008 | - | - | - |
| Model 3 | ||||||
| eGFR (per 1 ml/min/1.73 m2 increase) | 0.98 | 0.95–0.99 | 0.038 | 0.97 | 0.95–0.99 | 0.031 |
| Urinary PCR (per 1 mg/mg increase) | 1.86 | 1.42–2.44 | <0.001 | 1.71 | 1.32–2.21 | <0.001 |
| Tubular atrophy/interstitial fibrosis | ||||||
| 0–25% of cortical area (T0) | Reference | Reference | ||||
| 25–50% of cortical area (T1) | 8.20 | 0.97–69.4 | 0.053 | 8.50 | 1.01–71.43 | 0.049 |
| >50% of cortical area (T2) | 35.26 | 4.04–207.5 | 0.001 | 34.90 | 3.93–209.9 | 0.001 |
| Mesangial C3 deposition | ||||||
| 0 | Reference | Reference | ||||
| 1+ | 3.75 | 0.63–22.3 | 0.147 | 5.64 | 0.80–39.55 | 0.082 |
| 2+∼3+ | 8.76 | 1.39–55.2 | 0.021 | 14.03 | 1.86–105.77 | 0.010 |
| Serum C3 (per 1 mg/dl increase) | 0.95 | 0.93–0.98 | 0.004 | - | - | - |
| Patients with hypoC3 (vs. no) | - | - | - | 3.35 | 1.41–7.99 | 0.006 |
| Model 4 | ||||||
| eGFR (per 1 ml/min/1.73 m2 increase) | 0.97 | 0.95–0.99 | 0.030 | 0.97 | 0.95–0.99 | 0.021 |
| Urinary PCR (per 1 mg/mg increase) | 1.78 | 1.29–2.46 | <0.001 | 1.65 | 1.21–2.26 | 0.002 |
| Tubular atrophy/interstitial fibrosis | ||||||
| 0–25% of cortical area (T0) | Reference | Reference | ||||
| 25–50% of cortical area (T1) | 8.14 | 0.94–70.59 | 0.057 | 8.09 | 0.94–69.6 | 0.057 |
| >50% of cortical area (T2) | 32.41 | 3.61–191.44 | 0.002 | 30.42 | 3.31–179.2 | 0.003 |
| Mesangial C3 deposition | ||||||
| 0 | Reference | Reference | ||||
| 1+ | 4.58 | 0.62–33.70 | 0.135 | 7.25 | 0.69–58.89 | 0.064 |
| 2+∼3+ | 10.17 | 1.33–77.9 | 0.026 | 16.18 | 1.89–138.36 | 0.011 |
| Serum C3 (per 1 mg/dl increase) | 0.96 | 0.93–0.99 | 0.019 | - | - | - |
| Patients with hypoC3 (vs. no) | - | - | - | 2.73 | 1.09–6.86 | 0.032 |
Data are reported as hazard ratio (HR) and 95% confidence interval (CI).
Model 1: age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment, and serum C3 levels.
Model 2: age, sex, presence of gross hematuria, mean arterial blood pressure, eGFR, proteinuria, treatment, and pathologic findings.
Model 3: Model 2+serum C3 levels.
Model 4: Model 3+BMI, total cholesterol, and serum albumin.
eGFR, estimated glomerular filtration rate; PCR, protein-to-creatinine ratio.